Bristol Myers Squibb Company $BMY Position Lifted by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund raised its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 4.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 778,865 shares of the biopharmaceutical company’s stock after acquiring an additional 31,723 shares during the quarter. Bristol Myers Squibb makes up 0.5% of Illinois Municipal Retirement Fund’s portfolio, making the stock its 21st largest holding. Illinois Municipal Retirement Fund’s holdings in Bristol Myers Squibb were worth $48,601,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of BMY. Davis Asset Management L.P. purchased a new position in Bristol Myers Squibb during the second quarter valued at $27,000. Addison Advisors LLC bought a new stake in Bristol Myers Squibb during the second quarter valued at about $32,000. Groupe la Francaise increased its position in Bristol Myers Squibb by 562.9% in the second quarter. Groupe la Francaise now owns 590 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 501 shares in the last quarter. Arlington Trust Co LLC purchased a new stake in Bristol Myers Squibb in the second quarter worth about $35,000. Finally, Kilter Group LLC purchased a new stake in Bristol Myers Squibb in the second quarter worth about $35,000. Institutional investors own 76.41% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on BMY shares. Royal Bank Of Canada reaffirmed a “sector perform” rating on shares of Bristol Myers Squibb in a research report on Monday, October 19th. Daiwa Securities Group boosted their price objective on Bristol Myers Squibb from $53.00 to $66.00 and gave the company a “neutral” rating in a research note on Tuesday, August 4th. BMO Capital Markets reissued a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, July 27th. The Goldman Sachs Group upgraded shares of Bristol Myers Squibb from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 16th. Finally, Morgan Stanley decreased their target price on shares of Bristol Myers Squibb from $41.00 to $40.00 and set an “underweight” rating on the stock in a research note on Friday, October 30th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Bristol Myers Squibb has an average rating of “Hold” and an average price target of $65.46.

Bristol Myers Squibb Trading Up 1.1%

Shares of Bristol Myers Squibb stock opened at $62.80 on Wednesday. The company has a market capitalization of $128.37 billion, a P/E ratio of 13.92, a P/E/G ratio of 0.32 and a beta of 0.20. The company has a debt-to-equity ratio of 1.79, a quick ratio of 1.44 and a current ratio of 1.59. The company has a fifty day moving average of $62.17 and a 200 day moving average of $60.19. Bristol Myers Squibb Company has a fifty-two week low of $45.26 and a fifty-two week high of $68.64.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.10 by $0.25. The business had revenue of $13.07 billion during the quarter, compared to analyst estimates of $12.72 billion. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. Bristol Myers Squibb’s revenue for the quarter was up 6.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.63 EPS. On average, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.45 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd were paid a $0.63 dividend. The ex-dividend date of this dividend was Friday, October 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.0%. Bristol Myers Squibb’s dividend payout ratio is 55.88%.

Insider Transactions at Bristol Myers Squibb

In related news, Director Julia A. Haller sold 3,800 shares of Bristol Myers Squibb stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $63.31, for a total transaction of $240,578.00. Following the sale, the director owned 30,279 shares of the company’s stock, valued at approximately $1,916,963.49. This trade represents a 11.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Phil M. Holzer sold 500 shares of the business’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the transaction, the senior vice president directly owned 16,862 shares in the company, valued at approximately $1,138,185. This represents a 2.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.05% of the company’s stock.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.